ContraFect Corporation (CFRXQ)

Market Cap	5.35K
Revenue (ttm)	n/a
Net Income (ttm)	-24.14M
Shares Out	10.70M
EPS (ttm)	-5.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,470
Average Volume	2,304
Open	0.0005
Previous Close	0.0001
Day's Range	0.0005 - 0.0005
52-Week Range	0.0000 - 0.1400
Beta	-12.41
RSI	68.12
Earnings Date	n/a

About Blueprint Medicines

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 23
• Stock Exchange: OTCMKTS
• Ticker Symbol: CFRXQ